Alzheimer’s drug Leqembi, which slows disease progression, gets full FDA approval
The Food and Drug Administration (“FDA”) announced they have fully approved the first drug shown to slow down Alzheimer’s disease. Leqembi, whose generic name is lecanemab, should be widely covered by the federal Medicare health insurance program,